UCB: creating value for patien ts. Company Overview Oct. 2017
|
|
- Beatrice Simpson
- 5 years ago
- Views:
Transcription
1 UCB: creating value for patien ts Company Overview Oct. 2017
2 UCB: reinventing itself, leveraging a solid heritage : Emmanuel Janssen establishes UCB in Brussels 1972: A new stateof-the-art R&D center in Brainel Alleud, Belgium 1990s: approval of Keppra, a novel anti-epileptic 2006: UCB acquires German pharma company Schwarz Pharma Combine leadership in antibody research & chemistry expertise to better treat severe diseases 1936: UCB enters the United States 1952: UCB discovers Atarax U.S. license awarded to Pfizer 1980s: UCB registers its novel antihistamine Zyrtec 2004: UCB acquires British biotech company Celltech Launch of Cimzia, Vimpat & Neupro Launch of a new anti-epileptic s 1990s Today Chemical Group Primary Care Pharma Specialty Bio-pharma
3 UCB: creating value for patients Bringing solutions to people living with neurological or immunological diseases 3 Key facts and figures 2016: Revenue: 4.2 billion rebitda: 1031 million More than 7500 employees globally Operations in ~40 countries R&D Spend: 24% of revenue Listed on Euronext
4 A global and diverse workforce 4 73 NATIONALITIES 50/50 MEN/WOMEN FY 2016 figures
5 3 core medicines for patients with severe diseases 5 Rheumatoid arthritis Psoriatic arthritis (PSA) Ankylosing spondylitis (AS) Axial spondyloarthritis (AxSpA) Crohn s disease Epilepsy Parkinson s disease Restless legs syndrome
6 Briviact (brivaracetam) 6 Our new anti-epileptic drug Quick facts Approved in Europe (Jan. 2016) and U.S. (Feb. 2016) as adjunctive therapy Received monotherapy label in the U.S. (Sep. 2017) Available in 12 countries Reached more than patients * worldwide Expected peak sales of at least 400 million ** * FY 2016 ** By 2026
7 Other key products 7 Keppra (levetiracetam) Epilepsy adjunctive therapy (also in monotherapy in Europe) Sold as E Keppra in Japan Keppra XR (levetiracetam Extended-release tablets) Epilepsy adjunctive therapy U.S. only Zyrtec (cetirizine HCl) Seasonal allergic rhinitis Xyzal (levocetirizine dihydrochloride) Allergies and chronic idiopatic urticaria
8 Drug Development timelines Compound Attrition Rates Production Scales 8 Lab Scale Pilot Scale Industrial Scale Early R&D 2-4Y Pre- Clinical 1Y Phase I Phase II Phase III Approval Market 1-2Y 2Y 2-3Y 1-2Y Total:9-12Y Compound Attrition
9 9 R&D investors in Europe The 2016 EU Industrial scoreboard by R&D intensity % (top 60) 26,0 24,0 22,0 20,0 18,0 16,0 14,0 12,0
10 10 R&D Investors Belgium (Millions )
11 A promising pipeline for differentiating solutions Evenity TM (romosozumab) osteoporosis UCB0942 (PPSI) highly drug resistant epilepsy dapirolizumab pegol (CD40L antibody) systemic lupus erythematosus bimekizumab (IL17 A/F) various skin and arthritis indications Phase 1 Phase 2 Phase 3 Filing Phase 2a results: Q Phase 2b results: H Partner: Biogen Phase 2b results: Q / Q Partner: Amgen 11 bimekizumab add-on to Cimzia rheumatoid arthritis seletalisib (PI3K delta inhibitor) immunology indications UCB7665 (anti-fcrn) immunology indications UCB1332 Parkinson s disease UCB4144 / VR942 asthma UCB6673 immunology indications UCB3491 epilepsy UCB7858 immunology indications Phase 2a results: Q Phase 2a results: Q Phase 2a results: Q Partner: Neuropore Partner: Vectura Partner: King s College London neurology immunology
12 Braine in 5 figures Braine Overview Eric Browaeys Site Director
13 964 13
14 54 14
15 500 15
16 40 16
17
18 BIO-PILOT GALENIC 18 PROCESS DEVLPT CHEMICAL PACKAGING R&D ADMIN
19 Green Strategy 19
20 20 Limit increase global temperature to well below 2 C Reduce CO2 emissions by at least 25% by 2030
21 CO2 Neutrality by 2075! Potential Scenarios (IPCC) 21 = «as is» = limiting temp rise to 2 C
22 Impact of Scenarios 22 AS IS 1900 Now : +-1 C + COP Now: +- 20cm +
23 UCB Strategy 23
24 Scope Scopes 1&2(66 kt) Scope 3 UCB Total footprint : 430 kt (2015 baseline) Neutrality scope: 175 kt (2015 baseline) 24 Our sites Transport Devices &Packaging Suppliers CMOs CARBON NEUTRALITY by 2030 BEST EFFORTS
25 UCB s 2015 Yearly Emissions = ~ 175 kt of CO2 (excluding CMOs & Suppliers) 25 8% 5% 4% Production sites Business travel (air) 30% Transport - Supply chain (estimated) 12% Fleet (estimated) Key Affiliates (incl Slough) 17% Employee Commuting (estimated) 24% Product end of life (packaging) Waste
26 UCB Emissions = 1 Airbus A380 in flight 24/24 26
27 Reduction Milestones % 100% 80% 95% 80% 65% RENEWABLE ENERGY ENERGY EFFICIENCY CHANGING BEHAVIOURS 60% 40% 20% 2020 : -5% 2025: -20% 2030: -35% 2050: -70% 30% 0%
28 Offsetting 28 Forests are Carbon Sinks: 1 Ha = 7 tons CO 2 /year
29 How? Right Balance between 29 Reduction and Offsetting 80% 20%
30 CO 2 Agenda to reach Carbon Neutrality by % 100% 80% 60% 95% 50% 80% 65% RENEWABLE ENERGY ENERGY EFFICIENCY CHANGING BEHAVIOURS 40% 30% 15% 20% 0% Scopes 1&2 0% 0% % Reduction Off setting Total -40% -60% -80% -45% -65% -65% REFORESTATION AVOIDING DEFORESTATION
31 31 What do we do already? Reduction
32 32 92% 55% in 2015
33
34 Cogeneration Principle Annual electrical production : +/- 5,000,000 [kw34h] Annual heat production : +/- 7,000,000 [kwh] CO2 savings : 1,000 tons/year (3% of Braine emissions) Investment: 1,500,000 Operational : Q ELECTRICITY 40% HEAT 90% 58%
35 Global Supply chain ACCOMPLISHMENTS 35 Intermodal Optimization
36 36
37 Fleet & Business Travel Number of vehicles >< Average CO² levels % Petrol + EV, HEV, PHEV: 1 January 2018 for BE; June 2018 for UK, DE, NL, US 0 ASIA UCB EUROPE UCB NORTH AMERICA UCB SOUTH AMERICA 0 Vehicle count Average CO2 Value Business Travel: we target a 30% reduction in 2018
38 Green Teams 38 = Self organized groups of employees located in Braine (8) and HQ working together to reduce their ecological footprint = 1200 Trees / Year for Belgium We will use recycled paper
39 39 What do we do already? Offsetting
40 2 projects of Reforestation: Virunga Park, DR Congo Ethiopia TCO2 by 2030 Partners: WWF CO2 Logic T CO2 by 2030 Partners: KUL We Forest Protecting the forests of the Virunga National Park
41 41 3 billion people in the world are still boiling their water and cooking their food on a fire between 3 stones Using cookstoves could save 50 to 70% of the wood they use and avoid deforestation
42 Avoid deforestation : Virunga Park, DR Congo TCO2 by 2030 Partners: WWF CO2 Logic Protecting the forests of the Virunga National Park
43 1 day UCB = 1 olympic swimming pool 43
44 100% 44
45 Our Environmental Commitments by % - 20% - 25%
46 Thanks!
UCB Inspired by patients. Driven by science.
UCB Inspired by patients. Driven by science. 3 months interim Report Brussels, 24 April 2017 Carolin, living with epilepsy and axial spondyloarthritis Disclaimer and safe harbor Forward-looking statements
More informationUCB presentation. Investor Relations April 24, 2014
UCB presentation Investor Relations April 24, 2014 Disclaimer and safe harbor 2 Forward-looking statements: This presentation contains forward-looking statements based on current plans, estimates and beliefs
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationUCB Inspired by patients. Driven by science Half-Year Results Brussels, 27 July 2017
UCB Inspired by patients. Driven by science. 2017 Half-Year Results Brussels, 27 July 2017 Disclaimer and safe harbor 2 Forward-looking statements This presentation contains forward-looking statements,
More informationmonth interim update
2016 9 month interim update Brussels, 25 October 2016 Mariana, living with epilepsy Disclaimer and safe harbor Forward-looking statements 2016 9M interim update - 2 This presentation contains forward-looking
More information2016 Half-Year Financial Results
2016 Half-Year Financial Results Brussels, 28 July 2016 Mariana, living with epilepsy Disclaimer and safe harbor Forward-looking statements 2 This presentation contains forward-looking statements, including,
More informationUCB Inspired by patients. Driven by science.
UCB Inspired by patients. Driven by science. Jean-Christophe Tellier, CEO Full Year 2016 Results Presentation Brussels, 23 February 2017 Carolin, living with epilepsy and axial spondyloarthritis Disclaimer
More information2013 half-year results. 31 July 2013
2013 half-year results 31 July 2013 Disclaimer and safe harbour 2 Forward-looking statements: This presentation contains forward-looking statements based on current plans, estimates and beliefs of management.
More informationUCB Inspired by patients. Driven by science. 9 month interim report Brussels, 30 October 2018
UCB Inspired by patients. Driven by science. 9 month interim report Brussels, 30 October 2018 Disclaimer and safe harbor Forward-looking statements 2 This presentation contains forward-looking statements,
More informationUCB Inspired by patients. Driven by science full year financial report Brussels, 22 February 2018
UCB Inspired by patients. Driven by science. 2017 full year financial report Brussels, 22 February 2018 Disclaimer and safe harbor 2 Forward-looking statements This presentation contains forward-looking
More informationUCB Inspired by patients. Driven by science Half-Year Report Brussels, 26 July 2018
UCB Inspired by patients. Driven by science. 2018 Half-Year Report Brussels, 26 July 2018 Disclaimer and safe harbor Forward-looking statements 2 This presentation contains forward-looking statements,
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationFirstGroup corporate responsibility data
FirstGroup corporate responsibility data Created June 2017 Covering 2016/17 Summary This document provides the corporate responsibility data for FirstGroup for the reporting year 2016/17. Unless otherwise
More informationAnti-epilepsy Drug VIMPAT for I.V. infusion 200mg Launched in Japan
Press Release March 25, 2019 UCB Japan Co., Ltd. Daiichi Sankyo Company, Limited Anti-epilepsy Drug VIMPAT for I.V. infusion 200mg Launched in Japan UCB Japan Co., Ltd. (headquarters: Shinjuku-ku, Tokyo;
More informationUCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More informationHealth for Humanity 2020 Goals 2
2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More information2010 full-year results 2 March 2011
2010 full-year results 2 March 2011 Progressing to become the patient-centric global biopharma leader Alison, living with rheumatoid arthritis Disclaimer and safe harbour Forward-looking statements: This
More informationDainippon Sumitomo Pharma
Progressing Towards an Internationally Competitive R&D-Oriented Pharmaceutical Company Dainippon Sumitomo Pharma Masayo Tada President and CEO 29th Annual J.P. Morgan Healthcare Conference January 11,
More informationREVIEW OF PRODUCTS AND OPERATIONS
REVIEW OF PRODUCTS AND OPERATIONS Sales by product in this fiscal term (Total Sales: 145,302 million) Onon & Onon Dry Syrup : 33,599 million Opalmon Tablets : 28,330 million Kinedak Tablets : 22,934 million
More informationLeading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products
ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio
More informationCREATING SHARED VALUE Nestlé and Nestlé Purina in the U.S.
CREATING SHARED VALUE Nestlé and Nestlé Purina in the U.S. Nestlé and Nestlé Purina -- We re Focused on Creating Shared Value in Every Aspect of our Business: Nutrition, Quality & Food Safety Environment
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationPublication Plan 2017
Publication Plan 2017 A passion for turning high quality, independent research insights into actionable commercial intelligence. Why Spherix Global Insights? Our independent reports are designed, developed,
More informationGlobal Aspergillosis Drugs Market Professional Survey Report 2016
Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24
More informationBoston Scientific is advancing...
Boston Scientific is advancing... Our mission Our values Boston Scientific is dedicated to transforming lives through innovative Caring Meaningful Innovation High Performance medical solutions that improve
More informationThe next generation biopharma leader
The next generation biopharma leader Half Year 2008 Results UCB Group Analysts and Investors Presentation Lloyd and Alexander, living with epilepsy August 1, 2008 Disclaimer and safe harbour 2 Forward-looking
More informationNeo Solar Power Corporation. June, 2017
Neo Solar Power Corporation June, 2017 NSP at A Glance Founded: December, 2005 Products: Cells, Modules and Systems 2016 Year-End Capacity: Cell: > 2.20 GW Module: > 670 MW System: > 700 MW approved pipeline
More informationA world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP
A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market
More informationSolvay expands its specialty polymers offerings with Ryton PPS acquisition
Solvay expands its specialty polymers offerings with Ryton PPS acquisition Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationGELATIN & AKIOLIS. Because every bio-molecule counts. Pol Deturck EVP Chemicals & Organic Specialties
GELATIN & AKIOLIS Because every bio-molecule counts Pol Deturck EVP Chemicals & Organic Specialties Why our bioplatform is promising Dual service provider and highly reliable partner Akiolis, the 3 rd
More informationQuartalsberichte als Instrument der strategischen IR
Quartalsberichte als Instrument der strategischen IR Lassen Sie uns Zahlenfriedhöfe beerdigen. Nutzen wir Quartalsberichte, um dem Zahlenwerk unserer Unternehmen qualitative Information hinzuzufügen. Kommunizieren
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationUCB reinforces commitment to epilepsy community on European Epilepsy Day
For the attention of accredited medical and business writers UCB reinforces commitment to epilepsy community on European Epilepsy Day Marking 100,000 patients treated milestone for Vimpat (lacosamide)
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationUCB receives positive EU CHMP opinion for CIMZIA (certolizumab pegol) AutoClicks Prefilled Pen
UCB receives positive EU CHMP opinion for CIMZIA (certolizumab pegol) AutoClicks Prefilled Pen Brussels, Belgium September, 2016 UCB has announced that the European Medicines Agency s (EMA s) Committee
More information2010 full-year results 3 March 2011
2010 full-year results 3 March 2011 Progressing to become the patient-centric global biopharma leader Alison, living with rheumatoid arthritis Disclaimer and safe harbour Forward-looking statements: This
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationUCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting
UCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting Key data focus on inflammatory and osteoporosis in patient populations
More informationNeo Solar Power Corporation. October 27, 2017
Neo Solar Power Corporation October 27, 2017 NSP at A Glance Founded: August, 2005 Products: Cells, Modules and Systems 2016 Year-End Capacity Cell: > 2.20 GW Module: > 670 MW System: > 700 MW approved
More informationPartnering for Growth
Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities
More informationPROTON THERAPY. Proton Therapy Edition 2016 WORLD MARKET REPORT & DIRECTORY EDITION
Proton Therapy Edition 2016 PROTON THERAPY WORLD MARKET REPORT & DIRECTORY EDITION 2016 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy Edition
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationEngaging Patients in Research to Increase Efficiency and Generate Real-World Data
Engaging Patients in Research to Increase Efficiency and Generate Real-World Data Chris Kula-Przezwanski Partnering Director Quintiles Digital Patient Unit 2 THE ENVIRONMENT Research Challenges 2005: PRNewswire
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations Presentation April 2017 1 I Investor Relations presentation April 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationvz Strategic Transaction with Almirall
vz Strategic Transaction with Almirall in Respiratory Disease Accelerating AstraZeneca Respiratory Leadership July 30, 204 Long-term value generation and strong strategic fit Stronger inhaled portfolio
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationNew data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome
New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to
More informationTable of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7
Solvay Media Kit Table of Contents 1. About Solvay 3 1.1. Solvay at a Glance 4 1.2. Group Portfolio 5 2. Transforming Solvay 6 2.1. Solvay s Portfolio Upgrade 7 3. Organizing for the Future 9 3.1. Why
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationToward a healthier 2020
Toward a healthier 2020 How citizenship and sustainability can help more people live healthier lives Photo Credit: Peace Corps We re creating a new vision of health. A vision that expands the ways we ve
More informationCommercial Foodservice R&D&D&E. Dr. Frank Johnson Gas Technology Institute
Commercial Foodservice R&D&D&E Dr. Frank Johnson Gas Technology Institute Research in Foodservice >Foodservice is Unique People understand it > Everyone eats out > 44% at least once/week People worked
More informationPINOVA ESTER GUM 8BG STABILITY. SAFETY. SUSTAINABILITY.
STABILITY. SAFETY. SUSTAINABILITY. Trusted for over forty years, Pinova Ester Gum delivers reliable and effective emulsion stability. Ester Gum is used in an array of beverage types including sports drinks,
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationGlobal Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023
Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Psoriasis Pipeline Drugs Industry Sizing, Growth and Forecast
More informationMoving closer to people with allergy
Moving closer to people with allergy Investor Relations Presentation January 2017 1 I Investor Relations Presentation January 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationMedia Kit. September 2017
Media Kit September 2017 About Pear Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company s approach is to integrate clinically-validated software applications with
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationFRANKFURT SITE TOUR 2017
FRANKFURT SITE TOUR 2017 MEDIA INFORMATION FRANKFURT SITE TOUR 2017 CONTENTS FRANKFURT INSULIN CITY... 4 5 DIABETES BACKGROUNDER... 6 DIABETES STATISTICS... 7 DIABETES MEDICINES... 8 IMAGE BANK... 9 NOTES...
More informationLamictal (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1062DFR Publication Date: February 2013
Lamictal (Epilepsy) Forecast and Market Analysis to 2022 Reference Code: GDHC1062DFR Publication Date: February 2013 Executive Summary Lamictal (lamotrigine) Key Metrics in the Nine Major Pharmaceutical
More information11. December 2017 Marianne Birkeland Kjær
1 11. December 2017 Marianne Birkeland Kjær Presentation title Date 2 Agenda My Background Novo Nordisk Overview PhD and PostDoc opportunities How to apply for regular positions Novo Nordisk standard recruitment
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationGlobal Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016 Global Magnetic Resonance Imaging (MRI)
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationExperience from an SME in initiating clinical trials
Experience from an SME in initiating clinical trials Tom Vanthienen Senior Director RA & QA May 28, 2010 AGENDA Introduction PregLem Clinical trials at PregLem Experience with Phase III trials Lessons
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationNew long-term data on Cimzia (certolizumab pegol) presented at EULAR 2014 shows sustained outcomes in patients with spondyloarthritis
New long-term data on Cimzia (certolizumab pegol) presented at EULAR 2014 shows sustained outcomes in patients with spondyloarthritis For the attention of European journalists only New 96-week interim
More informationCO 2 EMISSIONS - MRV. Monitoring, Reporting & Verification. Lars B. Christensen Executive Vice President Brussels 5 December 2012
CO 2 EMISSIONS - MRV Monitoring, Reporting & Verification Lars B. Christensen Executive Vice President Brussels 5 December 2012 European Commission MRV December 2012 1 AGENDA NORDEN at a glance MRV - Monitoring
More informationBoehringer Ingelheim and investment in R&D. Volker Barkmann
Boehringer Ingelheim and investment in R&D Volker Barkmann I. Our Corporation Boehringer Ingelheim in brief Boehringer Ingelheim Center Our headquarters in Ingelheim, Germany Family-owned global corporation
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More information(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health. December 2018
(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health December 2018 Safe Harbor Statement All statements in this presentation that are not based on historical fact are forward looking statements.
More informationDutch Life Sciences November 24 th, Erik Dam, CBO
Dutch Life Sciences November 24 th, 2016 Erik Dam, CBO Unmet need for food ingredients with clinically proven health benefits Consumers want healthy foods and will pay more for them (Forbes 2015) Global
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationKeppra (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1061DFR Publication Date: February 2013
Keppra (Epilepsy) Forecast and Market Analysis to 2022 Reference Code: GDHC1061DFR Publication Date: February 2013 Executive Summary Keppra (levetiracetam) Key Metrics in the Nine Major Pharmaceutical
More informationJefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationUCB enhances epilepsy presence in Japan and China: positive Phase 3 study for VIMPAT
UCB enhances epilepsy presence in Japan and China: positive Phase 3 study for VIMPAT Phase 3 study evaluating VIMPAT as adjunctive therapy in the treatment of Japanese and Chinese adult patients with partial-onset
More informationGlobal Standard Radiography Film X-Ray Film Printer Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Standard Radiography Film X-Ray Film Printer Market Research Report 2016 Global Standard Radiography Film
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationGlobal Vitamin Market Professional Survey Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Vitamin Market Professional Survey Report 2016 Global Vitamin Market Professional Survey Report 2016 Publication
More informationExtrapolation in paediatric juvenile idiopathic arthritis: case study
Extrapolation in paediatric juvenile idiopathic arthritis: case study Ruth Oliver, PhD Laura Shaughnessy, PhD Philippa Charlton, MD MPH 17.MAY.2016 EMA workshop Extrapolation in juvenile idiopathic arthritis
More informationTHE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS...
V T THE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS... BRIEF DESCRIPTION The European Brain Council (EBC) is carrying out a new research project for 2015-2017 on The value of treatment
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationJTI Switzerland. JTI Schweiz 3
JTI Schweiz 3 Who we are 300 employees JTI has been manufacturing tobacco products in the Wiggertal area for over 45 years. The local market organization and the production facility in Dagmersellen (canton
More information